Jianfei Qian, PhD
Jianfei Qian received both his DVM and PhD in China. In 2002, he came to the US as a postdoctoral research fellow in Dr. Qing Yi’s lab at the University of Arkansas for Medical Sciences. In 2018, he was recruited as an assistant research professor at The Houston Methodist Research Institute. His research is focused on the development of novel immunotherapy methods to treat multiple myeloma (MM) and other cancers by using anti-tumor-specific monoclonal antibodies (mAbs), identifying new cancer-specific antigens, and developing novel tumor vaccines.
Qiang Wang, PhD
Qiang Wang received his PhD in Microbiology at University of Chinese Academy of Science where he focused on molecular mechanisms of Influenza A virus replication. During his postdoctoral training at Lerner Research Institute of Cleveland Clinic, Wang developed a series of experimental methods to investigate the cross-talk between the tumor microenvironment and multiple myeloma. He has broad interests in the regulation of myeloma intrinsic and extrinsic drug resistance. In his free time, he enjoys outdoor activities with his family, watching movies, and playing basketballs.
Chuanchao Zhang, PhD
Chuanchao Zhang received his PhD degree in Beijing institute of Genomics, Chinese Academy of Science. He previously worked on DNA damage response, long non-coding RNAs and small peptides. He is well trained in molecular and cell biology and proficient in systematic analysis pipeline for high-throughput sequencing data, including RNA-seq, Chip-seq, PAR-CLIP-seq, etc. His current project focus is on the regulation of multiple myeloma and intrigued by tumor immunity, such as CAR-T. Looking forward to participating in related work in the future.
Yufei Zhang, PhD
Yufei Zhang received his bachelor of medicine and PhD from Fudan University and became a postdoctoral fellow at Houston Methodist Hospital in 2024. He is a well-trained scientist in biomedical sciences with a broad background in medicine and immunology. His research interest cover translational and clinical study in cancer immunotherapy including CAR-T cell therapy and cancer vaccine.
Wei Wu, PhD
Wei Wu received his PhD in Biochemistry and Molecular Biology at University of Chinese Academy of Science in 2022, and started the postdoctoral fellow training from Jan, 2024. His present project focuses on investigating the cross-talk between the tumor microenvironment and multiple myeloma.
Rui Duan, PhD
Rui Duan received her PhD in Basic Medicine at Southern Medical University in Jun 2023, and started the postdoctoral fellow training at Houston Methodist Hospital from Dec 2023. Her present project focuses on exploring the CD8+ T cells-induced pyroptosis in the melanoma.
Qi Guo, PhD
Qi Guo earned his MD and PhD from Lanzhou University in 2022 and became a postdoctoral fellow at Houston Methodist Hospital in 2023. He is a well-trained scientist specializing in metabolic diseases, with a broad background in medicine and immunology. His research focuses on uncovering the relationship between cancer cell metabolism and the immune response.
Lu Shao, PhD
Lu Shao received her PhD at Center for Excellence in Molecular Cell Science of Chinese Academy of Science in 2024, where she focused on molecular mechanisms of how mitochondria protein regulates the STING signaling pathway. She started the postdoctoral fellow training at Houston Methodist Hospital from July 2025. She is a well-trained scientist in molecular and cell biology sciences, her present project is about the discovery of essential regulators influences multiple myeloma
Yu Xie, PhD
Yu Xie received his PhD in Biochemistry and Molecular Biology at Nankai University in 2024, and started the postdoctoral fellow training at Houston Methodist Hospital from July 2025. His present project focuses on exploring the function and regulation of T cells in carcinogenesis and cancer immunotherapy.
Mengqi Wang, PhD
Mengqi Wang received her MD in Basic Medicine at Tianjin Medical University in 2022 and started the postdoctoral fellow training at Houston Methodist Hospital from March 2025. Her present project focuses on exploring the key regulator in Multiple Myeloma malignant phenotype and chemoresistance